Lupeng Pharmaceuticals
Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.
Overview
Lupeng Pharmaceuticals develops next-generation small-molecule targeted drugs for malignant tumours and autoimmune diseases, focused on haematological cancers and the BTK, Bcl-2 and Bcl-xL pathways. Its site states that rocbrutinib (LP-168) is approved by China's NMPA and that lacutoclax (LP-108) has entered pivotal registration studies. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo: NCT07609823 (phase 2, A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL), NCT07609862 (phase 1/2, A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies), NCT05716087 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma) and NCT07189065 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +18
- phase 3 +3
- targets +2
- modalities +8
- regions +7
- registry trials +30
Rocbrutinib is an experimental small-molecule drug from Guangzhou Lupeng Pharmaceutical in phase 3 trials for mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.
An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.
Similar pages
not linked directly; found by shared links- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Mantle cell lymphoma, Rituximab.
- CompanySymBio Pharmaceuticals
Shares Bendamustine, Mantle cell lymphoma, Follicular lymphoma.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Mantle cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TreatmentCTX112
Shares Mantle cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Lenalidomide, Rituximab, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Shares Rocbrutinib, Mantle cell lymphoma.
- TrialA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Shares Bendamustine, Mantle cell lymphoma, Rituximab.